basroparib   Click here for help

GtoPdb Ligand ID: 12611

Synonyms: STP-1002 | STP1002
Compound class: Synthetic organic
Comment: Basroparib (STP1002) is an inhibitor of the poly (ADP-ribose) polymerase family enzymes tankyrase (TNKS) and tankyrase 2 (TNKS2) [3]. It was developed for anti-tumour potential, and is reported to be devoid of the the on-target gastro-intestinal toxicity that is associated with earlier tankyrase inhibitors. Tankyrase inhibition antagonises Wnt/β-catenin pathway signalling, a pro-proliferative pathway that is hyperactivated in a number of cancers [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 94.36
Molecular weight 421.4
XLogP 0.91
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1C2=C(C(=O)NC(=N2)N3CCN(CC3)C4=C(C=C(C=C4F)OCCOC)F)N=N1
Isomeric SMILES FC1=C(C(=CC(=C1)OCCOC)F)N2CCN(CC2)C=3NC(C4=C(N3)N(N=N4)C)=O
InChI InChI=1S/C18H21F2N7O3/c1-25-16-14(23-24-25)17(28)22-18(21-16)27-5-3-26(4-6-27)15-12(19)9-11(10-13(15)20)30-8-7-29-2/h9-10H,3-8H2,1-2H3,(H,21,22,28)
InChI Key ALDDPEMJJONRDI-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Basroparib (STP1002) has advanced to early stage clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04505839 First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors Phase 1 Interventional ST Pharm Co., Ltd.